Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); Updated Data for Btk Inhibitor PCI-32765 Support Comprehensive Program
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Pharmacyclics (NASDAQ: PCYC), PT $12.
Needham analyst says, "Looking into 2011, we believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Looking into 2011, we believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
